Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Acurx Pharmaceuticals, Inc. (ACXP : NSDQ)

• Company Description    Acurx Pharmaceuticals Inc. is a clinical stage biopharmaceutical company. It focused on developing new antibiotics to treat infections. Acurx Pharmaceuticals Inc. is based in STATEN ISLAND, N.Y. Number of Employees: 4

• Price / Volume Information    Yesterday's Closing Price: $0.50 Daily Weekly Monthly 20 Day Moving Average: 18,799,600 shares Shares Outstanding: 29.41 (millions) Market Capitalization: $14.67 (millions) Beta: -1.23 52 Week High: $3.33 52 Week Low: $0.30 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 51.17% 45.51% 12 Week 33.85% 12.59% Year To Date -38.70% -42.59%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 259 LIBERTY AVENUE - STATEN ISLAND,NY 10305 USA ph: 917-533-1469 fax: - davidluci@acurxpharma.com http://www.acurxpharma.com

• General Corporate Information    Officers David P. Luci - President; Chief Executive Officer and Director Robert J. DeLuccia - Executive Chairman Robert G. Shawah - Chief Financial Officer Carl V. Sailer - Director Joseph C. Scodari - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 00510M104 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/25 Next Expected EPS Date: 08/08/25 Share - Related Items Shares Outstanding: 29.41 Most Recent Split Date: (:1) Beta: -1.23 Market Capitalization: $14.67 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.11 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-0.45 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 1.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/08/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 4.84 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 60.71% vs. Previous Quarter: 31.25% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 06/30/25 - - 03/31/25 - -526.78 12/31/24 - -444.05 ROA 06/30/25 - - 03/31/25 - -223.78 12/31/24 - -220.98 Current Ratio 06/30/25 - - 03/31/25 - 1.93 12/31/24 - 1.19 Quick Ratio 06/30/25 - - 03/31/25 - 1.93 12/31/24 - 1.19 Operating Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Net Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Pre-Tax Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Book Value 06/30/25 - - 03/31/25 - 0.10 12/31/24 - 0.03 Inventory Turnover 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Equity 06/30/25 - - 03/31/25 - 0.00 12/31/24 - 0.00 Debt-to-Capital 06/30/25 - - 03/31/25 - 0.00 12/31/24 - 0.00

Powered by Zacks Investment Research ©